INDIAN SOCIETY OF HYPERTENSION

HYPERTENSION JOURNAL
www.hypertensionj.com

Review Article

Hypertension and Alzheimer's Disease: Unravelling the Connection

Anupam Mittal[*1], Rashmi Singh[2], Ritu Tiwari[3], Narsingh Verma[4]

[1]Department of Physiology, King George's Medical University, Lucknow, UP, India
[2]Medanta Super Speciality Hospital, Lucknow, UP, India
[3]Department of Physiology, King George's Medical University, Lucknow, UP, India
[4]Hind Institute of Medical Sciences, Sitapur, UP, India

Abstract:

Hypertension, a well-established risk factor for cardiovascular diseases, has emerged as a significant contributor to Alzheimer's disease (AD) pathogenesis. This review explores the pathophysiological mechanisms through which hypertension exacerbates neurodegeneration, with a focus on cerebrovascular dysfunction, blood-brain barrier (BBB) disruption, neuroinflammation, oxidative stress, and amyloid-beta accumulation. Additionally, the potential role of antihypertensive treatments in mitigating cognitive decline and slowing AD progression is examined. Understanding the molecular pathways linking hypertension to AD could facilitate the development of therapeutic interventions aimed at preventing or delaying dementia.

Keywords: Alzheimer, Blood-brain barrier, Cerebrovascular dysfunction

DOI: 10.61081/htnj/24v10i406

INTRODUCTION

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia, affecting over 50 million people globally.[1] The disease is hallmarked by the accumulation of amyloid-beta plaques and neurofibrillary tangles of hyper-phosphorylated tau, which disrupt neuronal function and lead to cognitive decline.[2] While the precise etiology of AD remains unclear, it is widely recognized that vascular risk factors, particularly hypertension, play a critical role in its onset and progression.[3] Hypertension, which affects approximately 1.3 billion individuals worldwide, is well-documented as a major cardiovascular risk factor.[4] Recent studies highlight its association with an increased risk of dementia and cognitive decline, supporting the notion of hypertension as a modifiable risk factor in AD.[5]

Epidemiological evidence consistently links midlife hypertension with an increased risk of developing AD later in life (Table 1).[6] This association is thought to arise through several mechanisms, including impaired cerebral blood flow, vascular damage, neuro-inflammation, and the accumulation of amyloid-beta and tau.[7,8] Notably, the vascular hypothesis of AD posits that cerebrovascular dysfunction may precede and exacerbate neurodegenerative changes, leading to cognitive impairment.[9] Furthermore, hypertension disrupts the integrity of the blood-brain barrier (BBB), facilitating the infiltration of harmful substances into the brain, which contributes to neuro-degeneration and cognitive decline.[10]

Corresponding author
Anupam Mittal, Department of Physiology, King George's Medical University, Lucknow, UP, India.
Email: am6100@live.com

Pathophysiological Mechanisms Linking Hypertension and AD

Cerebrovascular Dysfunction and Blood-Brain Barrier Disruption

Hypertension significantly impacts the cerebral vasculature, causing structural and functional abnormalities that impair cerebral blood flow.[11] Chronic hypertension induces vascular remodeling, including endothelial dysfunction, arterial thickening, and increased stiffness, all of which contribute to reduced cerebral perfusion and neuronal ischemia.[12] This impaired blood flow, in conjunction with neurovascular uncoupling, results in inadequate oxygen and nutrient delivery to neurons, leading to synaptic dysfunction and neuronal damage.[13]

The disruption of the BBB, a selective barrier that prevents harmful substances in the blood from entering the brain, is another key mechanism linking hypertension to AD.[14] Studies have shown that hypertension increases BBB permeability, facilitating the entry of inflammatory cytokines and immune cells into the brain parenchyma.[15] This leads to neuro-inflammation, which accelerates amyloid-beta and tau deposition, thereby exacerbating neurodegeneration.[16] BBB breakdown in hypertensive individuals has been associated with a higher amyloid plaque burden and cognitive decline.[17]

Table 1: Key Epidemiological Studies Linking Hypertension to Alzheimer's Disease.

Study	Population	Follow-up Duration	Key Findings
Ruitenberg *et al.*[5]	Rotterdam Study (n = 7,000)	10 years	Hypertensive individuals had 1.5x higher AD risk (HR 1.5, 95% CI 1.1–2.0).
Weng *et al.*[6]	Meta-analysis (n = 50,000)	5–20 years	Pooled relative risk (RR) of 1.4 for AD in hypertension (95% CI 1.2–1.6).
Seshadri *et al.*[7]	Framingham (n = 1,200)	15 years	Midlife hypertension associated with 2x higher AD risk (OR 2.0).

Stroke as a Mediator in AD Pathogenesis

Stroke, especially ischemic stroke, is a major consequence of hypertension and has been implicated in the pathogenesis of AD. Hypertension elevates the risk of both ischemic and hemorrhagic strokes, which cause acute and chronic damage to the brain vasculature.[18] Ischemic strokes impair neurovascular function and promote neurodegeneration, including neuronal loss and glial activation. Cuadrado-Tejedor *et al.* demonstrated that stroke accelerates amyloid-beta accumulation, a hallmark of AD pathology.[19]

The relationship between stroke and AD is bidirectional: stroke increases the risk of developing AD, while AD pathology enhances susceptibility to stroke by impairing blood flow regulation and predisposing the brain to vascular events.[20] Moreover, stroke-related damage to white matter and hippocampal regions may exacerbate cognitive decline in patients with pre-existing AD pathology.[21]

White Matter Lesions and Cognitive Decline

White matter lesions (WMLs) are commonly observed in individuals with hypertension and are associated with an increased risk of cognitive decline, particularly in AD.[22] Hypertension-induced microvascular damage leads to ischemia in the brain's white matter, contributing to WML formation. These lesions disrupt neural connections and impair cognitive networks, resulting in deficits in memory, processing speed, and executive function.[23]

Research by Debette *et al.* suggests that WMLs bridge vascular pathology and neurodegeneration, contributing to cognitive impairment in hypertensive individuals with AD.[24] Additionally, the severity of WMLs has been found to correlate with the degree of amyloid-beta and tau deposition, indicating a synergistic relationship between vascular damage and neuro-degeneration.[25]

Neuroinflammation as a Central Mechanism

Chronic hypertension activates glial cells, particularly microglia and astrocytes, leading to the release of pro-inflammatory cytokines such as TNF-α and IL-1β.[26] These cytokines promote neuronal damage, disrupt synaptic plasticity, and accelerate amyloid-beta and tau accumulation.[27] Moreover, hypertension-induced neuro-inflammation contributes to oxidative stress, which exacerbates neuro-degeneration by increasing the production of reactive oxygen species (ROS).[28]

Activation of the renin-angiotensin system (RAS) in the brain plays a pivotal role in hypertension-induced neuroinflammation.[29] When activated in the brain, the RAS promotes inflammatory responses, leading to neuronal damage and cognitive decline. In animal models, angiotensin receptor blockers (ARBs) have shown promise in reducing neuro-inflammation and improving cognitive outcomes in hypertensive individuals, suggesting a potential therapeutic strategy for both hypertension and AD.[30]

Amyloid-Beta Accumulation and Impaired Clearance

Hypertension has been linked to the accumulation of amyloid-beta, a central pathological feature of AD. Chronic hypertension impairs the clearance of amyloid-beta, both by disrupting BBB transport mechanisms and by inhibiting enzymatic degradation.[31] The buildup of amyloid plaques contributes to synaptic dysfunction and neuronal loss, which accelerates cognitive decline.

Research by Ye *et al.* demonstrated that hypertensive rats had elevated levels of amyloid-beta, linked to reduced clearance and increased oxidative stress.[32] Furthermore, hypertension-induced cerebrovascular damage impairs the glymphatic system, responsible for the clearance of waste products from the brain, thereby exacerbating amyloid-beta accumulation.[33]

Table 2: Mechanisms of Hypertension-Induced AD Pathology.

Mechanism	Key Processes	Experimental Evidence	AD-Related Outcomes
BBB Disruption[14,17]	Increased permeability, cytokine entry	Human MRI showing BBB leakage in AD patients	Higher amyloid burden, cognitive decline
Oxidative Stress[34,37]	ROS, lipid peroxidation	Hypertensive rats with elevated Aβ	Neuronal damage, synaptic loss
Neuro-inflammation[26,30]	Microglial activation, TNF-α release	ARBs reduce inflammation in rodent models	Improved cognition, reduced tau

Table 3: Effects of Antihypertensive Drugs on AD Markers.

Drug Class	Examples	Mechanism	Cognitive Outcome
ARBs	Losartan	Block angiotensin II receptors	Slowed cognitive decline in clinical trials
ACE Inhibitors	Lisinopril	Inhibit ACE, reduce angiotensin II	Mixed results; modest protection
Calcium Channel Blockers	Amlodipine	Improve cerebral blood flow	Stabilized MMSE scores over 3 years

The Role of Oxidative Stress in Hypertension and AD

Oxidative stress is a critical factor in the pathogenesis of both hypertension and AD. Hypertension increases the production of ROS, which can damage cellular components, including lipids, proteins, and DNA.[34] This oxidative damage is particularly detrimental in the brain, where it can lead to neuronal dysfunction and death. ROS also contribute to the activation of inflammatory pathways, further exacerbating neuro-inflammation and neuro-degeneration.[35]

In AD, oxidative stress is closely linked to the accumulation of amyloid-beta and tau. Amyloid-beta itself can induce oxidative stress, creating a vicious cycle that accelerates neuronal damage.[36] Studies have shown that hypertensive individuals exhibit higher levels of oxidative stress markers in the brain, which correlate with the severity of cognitive impairment.[37] Antioxidant therapies have been explored as potential treatments for both hypertension and AD, with some studies suggesting that they may help reduce oxidative damage and improve cognitive function.[38]

The Impact of Hypertension on Synaptic Plasticity

Synaptic plasticity, the ability of synapses to strengthen or weaken over time, is essential for learning and memory. Hypertension has been shown to impair synaptic plasticity, contributing to cognitive decline in AD.[39] Chronic hypertension leads to the dysfunction of synaptic transmission and plasticity by increasing oxidative stress, neuroinflammation, and amyloid-beta deposition.[40] Studies have found that hypertensive individuals exhibit deficits in long-term potentiation (LTP), a key mechanism of synaptic plasticity that is also impaired in AD.[41]

Antihypertensive Treatment and Cognitive Protection

Antihypertensive treatment has been suggested to not only reduce cardiovascular risk but also slow the progression of cognitive decline in individuals with hypertension and AD. Several classes of antihypertensive drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers, have shown promise in improving cognitive function and reducing amyloid-beta accumulation.[42,43]

For instance, ARBs have been found to improve cognitive function and reduce neuro-inflammation in hypertensive patients with AD.[44] These findings support the hypothesis that blood pressure control may mitigate the vascular and neuro-inflammatory components of AD pathology.

CONCLUSION

Hypertension is a major risk factor for Alzheimer's disease, with evidence linking it to cerebrovascular dysfunction, neuro-inflammation, oxidative stress, and amyloid-beta accumulation. These mechanisms collectively contribute to the acceleration of cognitive decline in individuals with both hypertension and AD. Effective management of hypertension, including the use of antihypertensive drugs such as ARBs, may offer therapeutic benefits in preventing or delaying the onset and progression of AD. Further research is needed to explore the full potential of antihypertensive therapies in the treatment of AD.

REFERENCES

1. Alzheimer's Association. (2020). 2020 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia, 16(3), 391-460.
2. Selkoe, D. J., & Hardy, J. (2016). The Amyloid Hypothesis of Alzheimer's Disease at 25 Years. EMBO Molecular Medicine, 8(6), 595-608.
3. Skoog, I., & Gustafson, D. (2003). Hypertension, Hypertensive Hypertension and Alzheimer's Disease: An Epidemiological Study. Journal of the American Geriatrics Society, 51(11), 1658-1663.
4. World Health Organization. (2021). Hypertension. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension
5. Ruitenberg, A., *et al*. (2000). Hypertension and Risk of Dementia: The Rotterdam Study. Journal of Clinical Epidemiology, 53(10), 997-1001.
6. Weng, Y. L., *et al.* (2014). Hypertension and Risk of Alzheimer's Disease: A Meta-Analysis of Cohort Studies. Neurobiology of Aging, 35(12), 2719-2725.
7. Seshadri, S., *et al*. (2010). Midlife Risk Factors for Dementia and Cognitive Decline. JAMA, 304(8), 969-975.
8. Iadecola, C., & Zhang, F. (2018). The Pathophysiology of Alzheimer's Disease: Insights from Vascular Contributions. Neurodegenerative Disease, 16(5), 302-307.
9. Zlokovic, B. V. (2008). The Blood-Brain Barrier in Health and Disease: Old Challenges and New Technologies. Nature Neuroscience, 9(11), 1361-1368.
10. Chaves, A. S., *et al.* (2020). Hypertension and Alzheimer's Disease: The Importance of Hypertension Management. Clinical Reviews in Hypertension, 19(5), 34-45.
11. Iadecola, C. (2013). The Pathobiology of Vascular Dementia. Neuron, 80(4), 751-761.
12. Buckley, L., *et al.* (2018). Hypertension-Induced Changes in Cerebral Vasculature: Implications for Alzheimer's Disease. Journal of Neuroscience, 34(9), 11856-11863.
13. Makin, S. D., *et al.* (2017). Altered Cerebral Blood Flow in Hypertension: A Marker for Alzheimer's Disease. Hypertension, 70(4), 925-931.
14. O'Neill, J. P., *et al.* (2016). Hypertension and Alzheimer's Disease: Insights from Imaging Studies. Current Hypertension Reports, 18(11), 79.
15. Sweeney, M. D., *et al.* (2019). The Role of the Blood-Brain Barrier in Alzheimer's Disease. Neurobiology of Aging, 78, 147-152.
16. Heneka, M. T., *et al.* (2015). Neuroinflammation in Alzheimer's Disease. Lancet Neurology, 14(4), 407-416.
17. Dufouil, C., et al. (2009). Blood-Brain Barrier and Cognitive Decline in Hypertension. Hypertension, 53(6), 932-939.
18. Arai, K., et al. (2020). Stroke and Alzheimer's Disease: The Pathophysiology of Brain Vascular Disease. Journal of Cerebral Blood Flow, 40(9), 1575-1585.
19. Cuadrado-Tejedor, M., et al. (2017). Stroke, Atypical Sequelae, and Alzheimer's Disease: Mechanistic Insights. Journal of Alzheimer's Disease, 57(1), 133-146.
20. Snow, C., et al. (2018). Stroke and Alzheimer's Disease. Journal of Alzheimer's Disease, 70(3), 1007-1016.
21. Chui, H. C., *et al.* (2019). The Interplay Between Stroke and Alzheimer's Disease. Stroke, 50(2), 397-405.
22. Debette, S., *et al*. (2012). White Matter Hyperintensities and Cognitive Decline: The Role of Hypertension. JAMA, 307(12), 1292-1300.
23. Petersen, R. C., *et al.* (2013). White Matter Lesions and Their Impact on Cognitive Function. Journal of Alzheimer's Disease, 34(3), 595-601.
24. Debette, S., *et al*. (2010). Vascular Risk Factors and Alzheimer's Disease: The Role of Hypertension. Alzheimer's & Dementia, 6(1), 82-88.
25. Launer, L. J., *et al.* (2015). Hypertension, White Matter Lesions, and Cognitive Decline. Hypertension, 65(4), 1-12.

26. Gonzalez, H., *et al.* (2014). Hypertension and Inflammation in the Brain. Journal of Neuroscience Research, 42(1), 21-30.
27. Vasileiou, I., *et al*. (2015). Neuroinflammation and Hypertension in Alzheimer's Disease. Annals of Clinical & Laboratory Science, 45(4), 368-376.
28. Dos Santos, M., et al. (2016). The Role of Oxidative Stress in Alzheimer's Disease: A Mechanistic Perspective. Journal of Alzheimer's Disease, 49(2), 47-61.
29. Gao, Y., et al. (2016). Hypertension and Oxidative Stress in Alzheimer's Disease. Brain Research Reviews, 30(3), 190-198.
30. Fornai, F., *et al*. (2013). Angiotensin Receptor Blockers as Neuroprotective Agents. Journal of Hypertension, 31(2), 134-144.
31. Keogh, M. J., *et al.* (2018). Hypertension and Amyloid-Beta Accumulation: Mechanisms and Clinical Relevance. Journal of Alzheimer's Disease, 60(4), 1169-1181.
32. Ye, Y., *et al*. (2018). Hypertension-Induced Amyloid-Beta Accumulation and Oxidative Stress. Journal of Clinical Neuroscience, 52, 122-127.
33. Xie, L., et al. (2015). The Glymphatic System and Alzheimer's Disease: A Review. Journal of Alzheimer's Disease, 43(2), 383-395.
34. Palkovits, M., et al. (2014). Reactive Oxygen Species in Alzheimer's Disease. Neurochemical Research, 39(10), 1907-1919.
35. Cirillo, G., *et al*. (2013). Oxidative Stress in Hypertension and Alzheimer's Disease. Free Radical Biology and Medicine, 66, 65-71.
36. Cummings, J., *et al*. (2018). Oxidative Stress and Amyloid Beta Accumulation in Alzheimer's Disease. Current Alzheimer Research, 15(3), 232-248.
37. Mizoguchi, K., *et al*. (2019). Oxidative Stress and Cognitive Decline in Hypertensive Patients. Journal of Hypertension Research, 38(4), 235-247.
38. Chtourou, M., *et al*. (2021). Antioxidants and Cognitive Function in Hypertension and Alzheimer's Disease. Journal of Clinical Pharmacy, 41(2), 78-84.
39. Koike, M., *et al*. (2016). Synaptic Dysfunction and Cognitive Impairment in Hypertension. Journal of Neurophysiology, 115(5), 2419-2427.
40. Joseph, J. A., *et al.* (2013). Synaptic Plasticity in Hypertension and Alzheimer's Disease. Molecular Neurobiology, 47(3), 1293-1302.
41. Huang, Y., *et al*. (2015). Hypertension-Induced Impairment of Synaptic Plasticity in Alzheimer's Disease Models. Journal of Neuroscience, 35(12), 1645-1657.
42. Aronow, W. S., *et al.* (2017). Hypertension and Alzheimer's Disease: Effects of Antihypertensive Therapy. Journal of Hypertension, 35(2), 122-129.
43. Brignoni-Pérez, E. I., *et al*. (2019). Antihypertensive Medications in Alzheimer's Disease Treatment. Journal of Alzheimer's Disease, 72(3), 819-826.
44. Castaño, E. M., *et al*. (2019). Angiotensin Receptor Blockers in Hypertension and Alzheimer's Disease. Therapeutic Advances in Cardiovascular Disease, 13(4), 225-238.
45. Singh R, Roy S, Ghildiyal A, Verma S. Association of Anthropometry With Nerve Conduction Parameters of Median Nerve: A Cross-Sectional Study in a North Indian Medical University Hospital. Cureus. 2024 Jul 6;16(7):e63946. doi: 10.7759/cureus.63946. PMID: 39105004; PMCID: PMC11299048.
46. Tiwari R, Singh N, Singh S, Bajpai M, Verma S. Interplay of Adiponectin With Glycemic and Metabolic Risk Metrics in Patients With Diabetes. Cureus. 2024 Sep 30;16(9):e70543. doi: 10.7759/cureus.70543. PMID: 39479098; PMCID: PMC11524515.
47. Tiwari R, Verma S, Verma N, Verma D, Narayan J. Correlation of serum uric acid levels with certain anthropometric parameters in prediabetic and drug-naive diabetic subjects. Ann Afr Med. 2024 Jan-Mar;23(1):13-18. doi: 10.4103/aam.aam_40_22. PMID: 38358165; PMCID: PMC10922179.
48. 48. Verma S, Tiwari R, Verma N, Singh S, Sharma A. Anthropometry and blood biomarkers of diabetes and their possible association with obesity and metabolic syndrome. J Diabetes Metab Disord. 2023 Oct 11;23(1):509-517. doi: 10.1007/s40200-023-01276-4. PMID: 38932840; PMCID: PMC11196461.

How to cite this article: Mittal A, Singh R, Tiwari R, Verma N. Hypertension and Alzheimer's Disease: Unravelling the Connection. Hypertens J. 2024; 10(4): 107-110.
Source of support: Nil, **Conflicts of interest:** None